v3.25.4
Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements, Research and Development Arrangements and In-Licensing Arrangements - In-Licensing Arrangements (Details) - USD ($)
$ in Millions
 1 Months Ended 12 Months Ended
Dec. 31, 2025
Jul. 31, 2025
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Acquired in-process research and development expenses     $ 1,613 $ 108 $ 194
YaoPharma [Member] | Licensing Agreements [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Upfront payment $ 150        
Maximum potential consideration $ 1,935   1,935    
3SBio [Member] | In-Licensing Agreement [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Upfront payment   $ 1,250      
Maximum potential consideration   4,800      
Equity investment   100      
3SBio [Member] | In-Licensing Agreement Option [Member]          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Upfront payment   100      
Option exercise fee   50      
Acquired in-process research and development expenses   $ 1,350 $ 1,350